Randomized Study of Imaging During Follow-Up After Surgery for High Risk Stage IIb-c and III Cutaneous Malignant Melanoma
Led by Uppsala University · Updated on 2024-12-16
1300
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether regular radiological assessments during follow-up after surgery for high-risk malignant melanoma improve patient survival. The study addresses concerns about the resource demands, potential radiation exposure, and anxiety caused by such imaging, especially given the recent introduction of effective medical treatments for melanoma. There is currently no clear evidence supporting routine imaging in this context.
Participants are randomly assigned to one of two groups. One group follows national guidelines with regular doctor appointments for 3 years, while the other group receives the same follow-up plus additional whole-body CT or PET scans and blood tests at baseline, 6, 12, 24, and 36 months. An interim analysis will be done after 1,000 patients enroll.
During the study, researchers will monitor overall survival at 5 years as the primary outcome. They will also assess quality of life through questionnaires over the 3-year follow-up. Participants will attend scheduled visits for clinical evaluations, imaging, and blood tests, with the study aiming to provide clear evidence about the role of imaging in post-surgical melanoma care.
CONDITIONS
Brief Title
A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
Research Team
G
Gustav J Ullenhag, professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Radical surgery for Cutaneous Malignant Melanoma stage IIb-c and III
Sufficient renal function for intravenous contrast scans
You will not qualify if you...
Assessed as unfit to receive treatment if melanoma recurs
Life expectancy less than 2 years due to other serious diseases
Unable or unwilling to provide informed consent
Unable to comply with follow-up program
Participation in other clinical trials affecting follow-up
Other malignancies within past 5 years except certain in situ cancers
Pregnancy or planned pregnancy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 3 years
Participants are assigned to routine follow-up or follow-up with additional radiological assessments including CT or PET scans and blood tests.
5 visits for scans and blood tests at baseline, 6, 12, 24, and 36 months
Long-term Monitoring
Duration - Up to 3 years
Participants continue follow-up with regular doctor's appointments according to national guidelines for ongoing assessment.
Regular doctor’s appointments as per national guidelines
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Study of Intismeran Autogene V940 Combined With Pembrolizumab Compared to Placebo Plus Pembrolizumab in People With Advanced Melanoma
Phase 1 Study Evaluating Safety and Tolerability of CTX-8371 in Adults With Advanced Cancers Receiving Intravenous Infusions
Study of CBA-1205 Antibody for Advanced Solid Tumors, Liver Cancer, Melanoma, and Pediatric Cancers Evaluating Safety and Tolerability
Phase II Randomized Trial of Intradermal IMO-2125 Tilsotolimod Injection Before Sentinel Node Biopsy in Patients with Advanced Primary Melanoma pT3-4 cN0M0
Randomized Study of Imaging During Follow-Up After Surgery for High Risk Stage IIb-c and III Cutaneous Malignant Melanoma
Phase III Study of Intravenous AMT-253 for Adults With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
Phase IbII Study of TCC1727 Combined With Benmelstobart, Olaparib, or Topotecan for Advanced Solid Tumors
Carbon Ion Radiation Therapy for Treating Mucosal Melanoma of the Female Lower Genital Tract
A Phase 2 Study Evaluating Progression-Free Survival and Local Control
Study of Faecal Microbiota Transplantation FMT Capsules for Treating Diarrhea and Colitis Caused by Immune Checkpoint Inhibitors in Patients with Melanoma or Kidney Cancer
National Cohort Study of Patients With Resectable or Unresectable Advanced Melanoma
Including Stage II, III, or IV and Primary Melanoma
Collecting Clinical, Biological, and Treatment Data Over 10 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.
TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.